This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kiriyama M, Ushikubi F, Kobayashi T et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217–224.
Hébert RL, Regnier L, Peterson LN. Rabbit cortical collecting ducts express a novel prostacyclin receptor. Am J Physiol 1995;268:F145–F154.
Takechi H, Matsumura K, Watanabe Y et al. A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem 1996;271:5901–5906.
Ishikawa T, Tamai Y, Rochelle JM et al. Mapping of the genes encoding mouse prostaglandin D, E, and F and prostacyclin receptors. Genomics 1996;32:285–288.
Toh H, Ichikawa A, Narumiya S. Molecular evolution of receptors for eicosanoids. FEBS Lett 1995;361:17–21.
Kedzie KM, Donello JE, Krauss HA et al. A single amino-acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. Mol Pharmacol 1998;54:584-590.
Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678–682.
Leigh PJ, Cramp WA, MacDermot J. Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem 1984;259: 12431–12436.
Tsai A, Hsu M-J, Vijjeswarapu H et al. Solubilization of prostacyclin membrane receptors from human platelets. J Biol Chem 1989;264:61–67.
Ito S, Hashimoto H, Negishi M et al. Identification of the prostacyclin receptor by use of [15-3H1]19-(3-azidophenyl)-20-norisocarbacyclin, an irreversible specific photoaffinity label. J Biol Chem 1992;267:20326–20330.
Boie Y, Rushmore TH, Darmon-Goodwin A et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 1994;269:12173–12178.
Katsuyama M, Sugimoto Y, Namba T et al. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett 1994;344:74–78.
Nakagawa 0, Tanaka I, Usui T et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 1994;90: 1643–1647.
Namba T, Oida H, Sugimoto Y et al. cDNA cloning of a mouse prostacyclin receptor. J Biol Chem 1994;269:9986–9992.
Sasaki Y, Usui T, Tanaka I et al. Cloning and expression of a cDNA for rat prostacyclin receptor. Biochim Biophys Acta 1994; 1224:601–605.
Smyth EM, Nestor PV, Fitzgerald GA. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996;271:33698–33704.
Pierce KL, Gil DW, Woodward DF et al. Cloning of the human prostanoid receptors, Trends Pharmacol Sci 1995;16:253–256.
Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995;1259: 109–120.
Ushikubi F, Hirata M, Narumiya S. Molecular biology of prostanoid receptors; an overview. J Lipid Mediators Cell Signal 1995; 12:343–359.
Chan CL, Lau HYA. Effects of prostanoids on immunologically activated rat mast cells. XXVI Annual Meeting of the European Histamine Research Society 1997;p59.
Hasse A, Bönisch D, Schrör K. Gene structure and expression of a prostacyclin receptor in vascular smooth muscle cells. Naunyn-Schmied Arch Pharmacol 1997;355:Rl9.
Hirata M, Ushikubi F, Narumiya S. Prostaglandin I receptor and prostaglandin D receptor. J Lipid Mediators Cell Signal 1995;12:393–404.
Narumiya S, Hirata N, Namba T et al. Structure and function of prostanoid receptors. J Lipid Mediators 1993;6: 155–161.
Kelly E, Keen M, Nobbs P et al. Segregation of discrete Gsα-mediated responses that accompany homologous or heterologous desensitization in two related somatic hybrids. Br J Pharmacol 1990;99:309–316.
Leigh PJ, MacDermot J. Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors. Br J Pharmacol 1985;85:237–247.
Schillinger E, Prior G. Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem Pharmacol 1980;29:2297–2299.
Rücker W, Schrör K. Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochem Pharmacol 1983;321:2405–2410.
Lombroso M, Nicosia S, Paoletti R et al. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins 1984;27:321–333.
MacDermot J, Barnes PJ. Activation of guinea pig pulmonary adenylate cyclase by prostacyclin. Eur J Pharmacol 1980;67:417–425.
MacDermot J, Barnes PJ, Waddell KA et al. Prostacyclin binding to guinea pig pulmonary receptors. Eur J Pharmacol 1981;75:127–130.
Lerner RW, Lopaschuk GD, Catena RC et al.[3H] Iloprost andprostaglandin E2 compete for the same receptor site on cardiac sarcolemmal membranes. Biochim Biophys Acta 1992;1105:189–192.
Schmid A, Thierauch K-H, Schleuning W-D et al. Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem 1995;228:23–30.
Kotani M, Tanaka I, Ogawa Y et al. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol 1995;48:869–879.
Sugimoto Y, Namba T, Honda A et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem 1992;267:6463–6466.
Breyer RM, Emeson RB, Tarng J-L et al. Alternative splicing generates multiple isoforms of a rabbit prostaglandin E2 receptor. J Biol Chem 1994;269:6163–6169.
Hall JM, Strange PG. The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci Reports 1984;4:941–948.
Watanabe T, Yatomi Y, Sunago S et al. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s. Blood 1991;78:2328–2336.
Jones RL, Qian Y, Wise H et al. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol 1997;29:525–535.
Buritova J, Honoré P, Besson JM. Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Pain 1996;67:379–389.
Merritt JE, Hallam TJ, Brown AM et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 1991;102:251–259.
Siegl AM, Smith JB, Silver MJ et al. Selective binding site for [3H] prostacyclin on platelets. J Clin Invest 1979;63:215–220.
Virgolini I, Li S, Sillaber C et al. Characterization of prostaglandin (PG)-binding sites expressed on human basophils. J Biol Chem 1992;267:12700–12708.
Watanabe Y, Suzuki M, Björkman M et al. Brain uptake of 11C-labelled stable prostacyclin receptor ligand studied by positron emission tomography. Neuroimage 1997;5:A1.
Kobayashi T, Kiriyama M, Hirata T et al. Identification of domains conferring ligand binding specificity to the prostanoid receptor. J Biol Chem 1997;272:15154–15160.
Blair IA, MacDermot J. The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br J Pharmacol 1981;72:435–441.
Blair IA, Leigh PJ, MacDermot J. Desensitization of prostacyclin receptors in a neuronal hybrid cell line. Br J Pharmacol 1982;77:121–127.
Barr DB, Duncan JA, Kiernan JA et al. Binding and biological actions of prostaglandin E2 and I2 in cells isolated from rabbit gastric mucosa. J Physiol 1988;405:39–55.
Town M-H, Schillinger E, Speckenbach A et al. Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioactive ligand. Prostaglandins 1982;24:61–72.
Sawai T, Negishi M, Nishigaki N et al. Enhancement by protein kinase C of prostacyclin receptor-mediated activation of adenylate cyclase through a calmodulin/myristoylated alanine-rich C kinasesubstrate (MARCKS)system in IC2 mast cells. J Biol Chem 1993;268:1995–2000.
Eggerman TL, Andersen NH, Robertson RP. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets. J Pharmacol Exp Ther 1986;236:568–573.
Kahn NN, Bauman WA, Sinha AK. Demonstration of a novel circulating anti-prostacyclin receptor antibody. Proc Natl Acad Sci USA 1997;94:8779–8782.
Blair IA, Hensby CN, MacDermot J. Prostacyclin-dependent activation of adenylate cyclase in a neuronal somatic hybrid: prostanoid structure-activity relationships. Br J Pharmacol 1980;69:519–525.
Oka M, Negishi M, Yamamoto T et al. Prostacyclin (PGI) receptor binding and cyclic AMP synthesis activities ofPGI1 analogues, SM-10906 and its methyl ester, SM-10902, in mastocytoma P-815 cells. Biol Pharm Bull 1994;17:74–77.
Hiroi T, Maruyama K, Hattori K et al. Affinity for [3H]iloprost bindingsites and CAMP synthesis activity of a 3-oxa-methano prostaglandin I1 analog, SM-10906, in human platelets and endothelial cells. Jpn J Pharmacol 1997;74:37–43.
Tanaka M, Kojima C, Muramatsu M et al. Binding affinities of isocarbacyclin methyl ester and its free acid to prostanoid receptors. Arzneim-Forsch 1995;45:967–970.
Armstrong RA, Lawrence RA, Jones RL et al. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br J Pharmacol 1989;97:657–668.
Seiler S, Brassard CL, Arnold AJ et al. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990;255:1021–1026.
Seiler SM, Brassard CL, Federici ME et al. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: (1) inhibition of platelet aggregation and mechanism of action. Thromb Res 1994;74:115–123.
Meanwell NA, Romine JL, Rosenfeld MJ et al. Non-prostanoid prostacyclin mimetics. 5. Structure-activity-relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid. J Med Chem 1993;36:3884–3903.
Seiler SM, Brassard CL, Federici ME et al. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins 1997;53:21–35.
Huang C, Tai H-H. Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. Biochem J 1995;307:493–498.
Negishi M, Harazono A, Sugimoto Y et al. Selective coupling of prostaglandin E receptor EP3D to multiple G proteins depending on interaction of the carboxylic acid of agonist and arginine residue of seventh transmembrane domain. Biochem Biophys Res Commun 1995;212:279–285.
Negishi M, Irie A, Sugimoto Y et al. Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of-α-carboxylic acidof agonist and arginine residue of seventh transmembrane domain. J Biol Chem 1995;270:16122–16127.
Smith JAM, Amagasu SM, Eglen RM et al. Characterization of prostanoid receptorevoked responses in rat sensory neurones. Br J Pharmacol 1998;124:513–523.
Oka M, Negishi M, Nishigaki N et al. Two types of prostacyclin receptor coupling to stimulation of adenylate cyclase and phophatidylinositol hydrolysis in a cultured mast cell line, BNu-2c13 cells. Cell Signal 1993;5:643–650.
Vassaux G, Gaillard D, Aihaud G et al. Prostacyclin is a specific effector of adipose cell differentiation. J Biol Chem 1992;267:11092–11097.
Turner JT, Camden JM, Kansra S et al. Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL. J Pharmacol Exp Ther 1992;263:708–716.
Schwaner I, Seifert R, Schultz G. Receptor-mediated increases in cytosolic Ca+2 in the human erythroleukaemia cell line involve pertussis toxin-sensitive and-insensitive pathways. Biochem J 1992;281:301–307.
Schwaner I, Seifert R, Schultz G. The prostacyclin analogues, cicaprost and iloprost, increase cytosolic Ca2+ concentration in the human erythroleukemia cell line, HEL, via pertussis toxin-insensitive G-proteins. Eicosanoids 1992;5:S10–S12.
Adachi M, Ryo R, Yoshida A et al. Elevation of intracellular calcium ion by prostaglandin E1 and its inhibition by protein kinase C in a human megakaryocyte leukemia cell line. Cancer Res 1989;49:3805–3808.
Feoktistov I, Breyer RM, Biaggioni I. Prostanoid receptor with a novel pharmacological profile in human erythroleukemia cells. Biochem Pharmacol 1997;54:917–926.
Vassaux G, Gaillard D, Darimont C et al. Differential response of preadipocytes and adipocytes to prostacyclin and prostaglandin E2: Physiological implications. Endocrinology 1992;131:2393–2398.
Vassaux G, Gaillard D, Aihaud G et al. Prostacyclin is a specific effector of adipose cell differentiation. J Biol Chem 1992;267:11092–11097.
Aubert J, Ailhaud G, Negrel R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Lett 1996;397:117–121.
Cazevieille C, Muller A, Meynier F et al. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int 1994;24:395–398.
Cazevieille C, Muller A, Bonne C. Prostacyclin (PGI2) protects rat cortical neurons in culture against hypoxia/reoxygenation and glutamate-induced injury. Neurosci Lett 1993;160:106–108.
Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 1996;48:413–463.
Premont RT, Inglesse J, Lefkowitz RJ. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 1995;9:175–182.
Smyth EM, Hong Li W, Fitzgerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. J Biol Chem 1998;273:23358–23266.
Murray R, Shipp E, Fitzgerald GA. Prostaglandin endoperoxide/thromboxane A2 receptor desensitization. J Biol Chem 1990;265:21670–21675.
Watanabe T, Sunaga S, Togo M et al. Protein kinase C plays a key role in the cross-talk between intracellular signalings via prostanoid receptors in a megakaryoblastic cell line, MEG-01s. Biochim Biophys Acta 1996;1304:161–169.
Neuschaferrube F, Hanecke K, Blaschke V et al. The C-terminal domain of the Gs-coupled EP4 receptor confers agonist-dependent coupling control to Gi but no coupling to Gs in a receptor hybrid with the Gi-coupled EP3 receptor. FEBS Lett 1997;401:185–190.
Audoly L, Breyer RM. Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. Mol Pharmacol 1997;51:61–68.
Corsini A, Folco GC, Fumagalli R et al. (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol 1987;90:255–261.
Ragazzi E, Chinellato A, Lille Ü et al. Pharmacological properties of MM-706, a new prostacyclin derivative. Gen Pharmacol 1995;26:703–709.
Jones RL, Qian YM, Wong HNC et al. Prostanoid action on the human pulmonary vascular system, Clin Exp Pharmacol Physiol 1997;24:I969–972.
Fassina G, Froldi G, Caparrotta L. A stable isosterically modified prostacyclin analogue, FCE-22176, acting as a competitive antagonist to prostacyclin in guinea-pig trachea and atria. Eur J Pharmacol 1985;113:459–460.
Caparrotta L, Ceserani R, Mongelli N et al. Depression and excitation induced in mice by two geometric isomers of (+)13,14-didehydro-20-methyl-carboprostacyclin, FCE 22177 and FCE 22176. Comparison with effects on blood pressure and platelet aggregation. Prostaglandins 1987;33:351–362.
Wilkins AJ, MacDermot J. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells. Eur J Pharmacol 1986;127:117–119.
Dong YJ, Jones RL, Wilson NH. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol 1986;87:97–107.
Lawrence RA, Jones RL, Wilson NH. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br J Pharmacol 1992;105:271–278.
Meanwell NA, Romine JL, Seiler SM. Non-prostanoid prostacyclin mimetics. Drugs Future 1994;19:361–385.
Merritt JE, Brown AM, Bund S et al. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. Br J Pharmacol 1991;102:260–266.
Armstrong RA, Jones RL, MacDermot J et al. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol 1986;87:543–551.
Wise H. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Prostaglandins Leukot Essent Fatty Acids 1996;54:351–360.
Wise H, Chow BS. Effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells. Prostaglandins Leukot Essent Fatty Acids 1996;S:S1 p35.
Wise H, Qian Y, Jones RL. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors. Eur J Pharmacol 1995;278:265–269.
Krane A, MacDermot J, Keen M. Desensitization of adenylate cyclase responses following exposure to IP prostanoid receptor agonists. Biochem Pharmacol 1994;47:953–959.
Giovanazzi S, Accomazzo MR, Letari O et al. Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 1997;325:71–77.
Edwards RJ, MacDermot J, Wilkins AJ. Prostacyclin analogues reduce ADP-ribosylation of the α-subunit of the regulatory Gs-protein and diminish adenosine (A2) responsiveness of platelets. Br J Pharmacol 1987;90:501–510.
Jaschonek K, Faul C, Schmidt H et al. Desensitization of platelets with iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol 1988;147:187–196.
Williams RJ, Kelly E. Gsα-dependent and-independent desensitisation of prostanoid-activated adenylyl cyclase in NG108-15 cells. Eur J Pharmacol 1994;268:177–186.
Krane A, Keen M. The effect of iloprost pretreatment on the sub-cellular localization of IP prostanoid receptors and Gsα in NG108-15 cells. Br J Pharmacol 1995;115:137P.
Krane A, Keen M. The effect of inhibitors of internalization on IP prostanoid receptor down-regulation in NG108-15 cells. Br J Pharmacol 1995;115:138P.
Keen M, Krane A. The effect of K+-depletedmediumoniloprost-andforskolin-mediated down-regulation of IP prostanoid receptors in NG108-15 cells. Br J Pharmacol 1996;117:72P.
Pearce D, Keen M. The effect of cycloheximide on IP prostanoid receptor down-regulation in NG108-15 cells. Br J Pharmacol 1995;116:19P.
Ashby B. Interactions among prostaglandin receptors. Receptor 1994;4:31–42.
Zucker T-P, Böznisch D, Hasse A et al. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998;345:213–220.
Bastepe M, Ashby B. The long cytoplasmic carboxyl terminus of the prostaglandin E2 receptor EP4 subtype is essential for agonist-induced desensitization. Mol Pharmacol 1997;51:343–349.
Nakagawa O, Sasaki Y, Tanaka I et al. Gene expression of prostacyclin receptor in the hypertrophied heart of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995;(Suppl 1):S270–S272.
Nakao K, Lesener B, Nakao K et al. Localization of the prostacyclin receptor in human kidney. Kidney International 1999;54:1899–1908.
Sasaki Y, Takahashi T, Tanaka I et al. Expression of prostacyclin receptor in human megakaryocytes. Blood 1997;90:1039–1046.
Oida H, Namba T, Sugimoto Y et al. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 1995;116:2828–2837.
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
(2002). Isolation, cloning and characterisation of IP-receptors. In: Prostacyclin and Its Receptors. Springer, Boston, MA. https://doi.org/10.1007/0-306-46822-0_4
Download citation
DOI: https://doi.org/10.1007/0-306-46822-0_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46308-2
Online ISBN: 978-0-306-46822-3
eBook Packages: Springer Book Archive